

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6170647

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST

**CONVEYING PARTY DATA**

Name	Execution Date
OXFORD FINANCE LLC, AS COLLATERAL AGENT	06/24/2020

**RECEIVING PARTY DATA**

<b>Name:</b>	REATA PHARMACEUTICALS, INC.
<b>Street Address:</b>	5320 LEGACY DRIVE
<b>City:</b>	PLANO
<b>State/Country:</b>	TEXAS
<b>Postal Code:</b>	75024

**PROPERTY NUMBERS Total: 60**

Property Type	Number
<b>Application Number:</b>	13085338
<b>Patent Number:</b>	8088824
<b>Patent Number:</b>	7915402
<b>Patent Number:</b>	7943778
<b>Patent Number:</b>	8071632
<b>Patent Number:</b>	8124656
<b>Patent Number:</b>	8124799
<b>Patent Number:</b>	8258329
<b>Patent Number:</b>	8309601
<b>Patent Number:</b>	8338618
<b>Patent Number:</b>	8394967
<b>Patent Number:</b>	8440820
<b>Patent Number:</b>	8440854
<b>Patent Number:</b>	8513436
<b>Patent Number:</b>	8633243
<b>Patent Number:</b>	8747901
<b>Patent Number:</b>	8993640
<b>Patent Number:</b>	9090574
<b>Patent Number:</b>	9102681
<b>Patent Number:</b>	9155721

PATENT

Property Type	Number
Patent Number:	9174941
Patent Number:	9233998
Patent Number:	9249089
Patent Number:	9278912
Patent Number:	9290536
Patent Number:	9464082
Patent Number:	9512094
Patent Number:	9556222
Patent Number:	9593074
Patent Number:	9670147
Patent Number:	9701709
Patent Number:	9796668
Application Number:	15791677
Patent Number:	9884809
Application Number:	15861758
Patent Number:	9889143
Application Number:	15861241
Patent Number:	RE45288
Patent Number:	RE45325
Application Number:	14466495
Application Number:	15433100
Application Number:	15548909
Application Number:	15615393
Application Number:	15622568
Patent Number:	8129429
Patent Number:	8455544
Patent Number:	9757359
Application Number:	15675862
Patent Number:	8778990
Application Number:	15760662
Application Number:	62660859
Application Number:	62660865
Application Number:	62674549
Application Number:	62627570
Application Number:	62671047
Application Number:	62535663
Application Number:	62580597
Application Number:	16115028

Property Type	Number
Application Number:	16130424
Application Number:	16157225

  
**CORRESPONDENCE DATA**

**Fax Number:** (415)693-2000  
*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 4156932000  
**Email:** crhem@cooley.com  
**Correspondent Name:** COOLEY LLP  
**Address Line 1:** 101 CALIFORNIA STREET, 5TH FLOOR  
**Address Line 4:** SAN FRANCISCO, CALIFORNIA 94111

<b>ATTORNEY DOCKET NUMBER:</b>	313879-104
<b>NAME OF SUBMITTER:</b>	C. RHEM
<b>SIGNATURE:</b>	/CR/
<b>DATE SIGNED:</b>	06/24/2020

**Total Attachments: 5**  
source=Reata-IP Security Interests Release Executed#page1.tif  
source=Reata-IP Security Interests Release Executed#page2.tif  
source=Reata-IP Security Interests Release Executed#page3.tif  
source=Reata-IP Security Interests Release Executed#page4.tif  
source=Reata-IP Security Interests Release Executed#page5.tif

## REASSIGNMENT AND RELEASE OF SECURITY INTEREST

This Reassignment and Release of Security Interest ("Release") is executed as of June 24, 2020, by OXFORD FINANCE LLC, a Delaware limited liability company, as collateral agent ("Assignor"), for the benefit of REATA PHARMACEUTICALS, INC., a Delaware corporation ("Assignee").

### RECITALS

WHEREAS, Assignee granted and pledged certain security interests in the intellectual property described on Exhibit A and Exhibit B (together, the "Intellectual Property") to the Assignor pursuant to the Intellectual Property Security Agreement, dated as of June 14, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the "Security Agreement"), and recorded with (a) the U.S. Patent and Trademark Office on June 14, 2018, at Reel/Frame 046357/0605, and on October 9, 2019, at Reel/Frame 050670/0902, with respect to patent security interests, and (b) the U.S. Patent and Trademark Office on June 14, 2018, at Reel/Frame 6353-0546, and on October 9, 2019, at Reel/Frame 6767/0489 with respect to trademark security interests; and

WHEREAS, Assignor wishes to release and reassign all interest that Assignor may have in the Intellectual Property as granted pursuant to the Security Agreement.

### NOW, THEREFORE, IT IS AGREED THAT:

Assignor releases, discharges, terminates and cancels all of its security interest in and to the Intellectual Property arising under the Security Agreement, and reassigns to Assignee, without warranty or recourse, all interest of Assignor in the Intellectual Property granted pursuant to the Security Agreement.

ASSIGNOR:

OXFORD FINANCE LLC

Address:

133 North Fairfax Street  
Alexandria, VA 22314  
Attn: Legal Department


By:   
Name: Colette H. Featherly  
Title: Senior Vice President

EXHIBIT A

<u>Description</u>	<u>Patent/App. No.</u>	<u>Issue/File Date</u>
Methods of treating obesity using antioxidant inflammation modulations	13085338	4/12/11
Novel forms of CDDO methyl ester	8088824	1/3/12
Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring	7915402	3/29/11
Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives	7943778	5/17/11
Antioxidant inflammation modulators: novel derivatives of oleanolic acid	8071632	12/6/11
Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring	8124656	2/28/12
Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17	8124799	2/28/12
Dehydroandrosterone analogs including an anti- inflammatory pharmacore and methods of use	8258329	9/4/12
Novel forms of CDDO methyl ester	8309601	11/13/12
Antioxidant inflammation modulators: novel derivatives of oleanolic acid	8338618	12/25/12
Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives	8394967	3/12/13
Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring	8440820	5/14/13
Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17	8440854	5/14/13
Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators	8513436	8/20/13
Novel forms of CDDO methyl ester	8633243	1/21/14
Delayed release, oral dosage compositions that contain amorphous CDDO-ME	8747901	6/10/14
2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof	8993640	3/31/15
Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring	9090574	7/28/15
Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17	9102681	8/11/15
Delayed release, oral dosage compositions that contain amorphous CDDO-ME	9155721	10/13/15
Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators	9174941	11/3/15
Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use	9233998	1/12/16

Description	Patent/App. No.	Issue/File Date
Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives	9249089	2/2/16
C13-hydroxy derivatives of oleanolic acid and methods of use thereof	9278912	3/8/16
C4 monomethyl triterpenoid derivatives and methods of use thereof	9290536	3/22/16
Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators	9464082	10/11/16
C17-heteroaryl derivatives of oleanolic acid and methods of use thereof	9512094	12/6/16
A-ring epoxidized triterpenoid-based antioxidant inflammation modulators and methods of use thereof	9556222	1/31/17
C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof	9593074	3/14/17
Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17	9670147	6/6/17
2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof	9701709	7/11/17
Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use	9796668	10/24/17
Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use	15791677	10/24/17
Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators	9884809	2/6/18
Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators	15861758	1/4/18
C17-heteroaryl derivatives of oleanolic acid and methods of use thereof	9889143	2/13/18
C17-heteroaryl derivatives of oleanolic acid and methods of use thereof	15861241	1/3/18
Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring	RE45288	12/9/14
Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring	RE45325	1/6/15
Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof	14466495	8/22/14
C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof	15433100	2/15/17
Imidazolyl tricyclic enones as antioxidant inflammation modulators	15548909	8/4/17
Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17	15615393	6/6/17
2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof	15622568	6/14/17
Synthetic triterpenoids and methods of use in the treatment of disease	8129429	3/6/12
Synthetic triterpenoids and methods of use in the treatment of disease	8455544	6/4/13
Synthetic triterpenoids and methods of use in the treatment of disease	9757359	9/12/17

<u>Description</u>	<u>Patent/App. No.</u>	<u>Issue/File Date</u>
Synthetic triterpenoids and methods of use in the treatment of disease	15675862	8/14/17
Betulinic acid derivative and method of use thereof	8778990	7/15/14
C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses	15760662	3/16/18
RORgammaT inverse agonists with an Indazole or Hexahydroindazole core	62660859	4/20/18
RORgammaT inverse agonists with an Indazole or Hexahydroindazole core	62660865	4/20/18
Pyridopyrazolopyrimidine Derivatives for the Treatment of Cystic Fibrosis	62674549	5/21/18
Co-crystal Forms of a Novobiocin Analog and Proline	62627570	2/7/18
Biaryl Amides with Modified Sugar Groups for Treatment of Diseases Associated with Heat Shock Protein Pathway	62671047	5/14/18
Methods of treating Alport Syndrome using Bardoxolone Methyl or Analogs Thereof	62535663	7/21/17
Methods of treating Alport Syndrome using Bardoxolone Methyl or Analogs Thereof	62580597	11/2/17
Antioxidant inflammation modulators: oleanolic acid derivatived with amino and other modifications at c-17	16115028	8/28/18
Methods of treating obesity using antioxidant inflammation modulators	16130424	9/13/18
Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof	16157225	10/11/18

EXHIBIT B

Trademarks

<u>Description</u>	<u>Serial No.</u>	<u>File Date</u>
REATA PHARMACEUTICALS	86778681	10/5/15
REATA PHARMACEUTICALS	86778679	10/5/15
REATA	86778689	10/5/15
REATA	86778692	10/5/15
Design	86778686	10/5/15
ENMOVRY	88601911	9/3/19
SKYLUMYS	88601907	9/3/19
SKYCLARYS	88601903	9/3/19
TREJOUVE	88601897	9/3/19
ENDLYSSO	88601892	9/3/19
ENDLYSSA	88601887	9/3/19